brazil
EN ES PT
Home
Welcome Note
Committees
Faculty
Timetable
Scientific Program
Satellite Symposia
Industry Advisory Board (IAB)
Abstract Submission
Poster Presentation
Poster Presentation Guidelines
List of Posters
Guided Poster Tours
Registration
Invitation Letter
Accommodation
CME
Sponsorship & Exhibition
Sponsors
Exhibitors
General Information
Tips and Hints
Transportation
Italian Agent
Chinese Agent
About Rio de Janeiro
Before you travel...
Endorsements
Partners
Previous and upcoming CODHy Congresses
The 2nd Latin America Congress on
Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy)

Rio de Janeiro, Brazil, March 22-25, 2012
  Timetable Print
 
Thursday, March 22, 2012
Welcome Reception - 19:30
Sponsored by Novo Nordisk

Friday, March 23, 2012
Hall A
09:00-10:30
Diabetes, Cardiovascular Diseases and Cancer
Insulin resistance: A multifaceted disease responsible for ASCVD and cancer
Diabetes, obesity and cancer
Diabetes therapy and cancer
Overview of diabetes in Latin America

10:30-11:00
Coffee Break
 
Hall A
Hall B
Hall C
11:00-12:30
Prevention and Early Therapy
Prediabetes therapy: Lifestyle/Drugs
First line therapy in T2D: Combination therapy vs. 
Monotherapy: 
Session 5
Hypertension Controversies
Should we change the target blood pressure in diabetic patients?
Yes/No
Should we avoid antihypertensive drugs that increase glucose/ obesity?
Yes/No
Session 8
Obesity
Current and future non-surgical weight loss therapy
Are there weight loss-independant effects of upper gastrointestinal tract diversion on diabetes?
How good is sleeve gastrectomy?
Bio Markers in diabetes and obesity
12:30-13:30
Lunch Break
13:30-15:15
Session 3
Utilization of Insulin Therapy by GPs
Are all sulfonylurea (Su) even?
Yes/No
Starting insulin therapy by GP: BASAL vs. Premix
Basal/Premix
Insulin intensification by GP
Yes/No
Session 6
RAAS in Diabetes
Is intracellular RAAS blockade a therapeutic target?
ACEs, ARBs or DRI: what is the best choice?
Is RAAS blockade indicated in every (T2D) patient
Oral Presentations
Session 9
Insulin Resistance/Beta Cell Role in Diabetes Progression
Tools to assess insulin resistance and Beta Cell function
Beta function: Evaluation and clinical applications
Insulin secretion and Insulin resistance: A dynamic interaction
15:15-15:45
Coffee Break
15:45-17:00
Session 4
The Voice of China

Treatment of Type 2 diabetes with traditional Chinese medicine 

Relationship of Urinary Bisphenol A Concen-tration to Risk for Prevalent Type 2 Diabetes in Chinese Adults 

The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study

Stratifying and tailoring HbA1c control targets for adults with Type 2 diabetes: Interpretation of the consensus proposed by the Chinese Society of Endocrinology

Session 7
Meet the Professor: Metabolic Syndrome
Metabolic Syndrome: Do we need this definition?
Testosterone for the management of Metabolic Syndrome
Intolerance to statin/target HDL
Yes/No
Session 10
New Insights to Neuropathy in T2D
Peripheral Neuropathy and small fibers: Diagnosis and therapeutic approach
CAN: A tool to assess the diagnosis by the diabetologist
The brain: New insights with diabetes, Alzheimer and depression
17:00-19:00
SGLT2 Inhibition and the ‘CODHy’ Controversies: Glycaemic Control and Beyond
Satellite Symposium sponsored by Bristol-Myers Squibb & AstraZeneca
This educational programme is accredited by the Royal College of Physicians of the United Kingdom for 2 credits
Hall C

Saturday, March 24, 2012
Hall A
Hall B
Hall C
09:00-10:30
Session 11
Type 2 Diabetes (T2D)
Can we stop Beta Cell destruction?
Yes/No
Early insulin therapy
Yes/No
Session 15
Hypertension Therapy in T2D
Diabetes and resistant hypertension
Managing combination antihypertensive therapy
What is the fourth drug?
New strategies: Baroreceptor devices and renal denervation
Session 19
Glucose Therapy
Should we aim at normal glycaemia or an individual approach?
Normal glycaemia/
Individual approach
Different goals with different therapies
Algorithm for T2D in Brazil
10:30-11:00
Coffee Break
11:00-12:30
Session 12
Targeting the Kidney
(Supported by an unrestricted educational grant from Boehringer Ingelheim and Eli Lilly and Company)

The kidney and its role in Glucose Homeostasis
Glucosuria as a novel approach in diabetes management
SGLT2 Safety barriers
Session 16
Hypoglycaemia
Good or Bad?
Good/Bad
Similar importance in every patient?
Yes/No
Can it be prevented?
Yes/No
Interrelationship Between CVD and Diabetes: Focusing on the Incretin System
(Supported by an unrestricted educational grant from Merck Sharp & Dohme)
The rationale for early and aggressive treatment of CVD risk factors in T2DM
Potential CVD effects of incretin-based therapies
12:30-13:30
Lunch Break
13:30-15:15
Oral Presentations
 
Session 17
New Data on Glycaemic Effects of Incretin Based Therapy in T2D
The vascular system and heart
The brain
The liver
Oral Presentations
Session 21
Bariatric Surgery
Minimal requirements to perform bariatric surgery
Do we have long term data to support efficacy and safety?
Yes/No
Surgery in mild obesity and T2D
1st line/ 2nd line
15:15-15:45
Coffee Break
15:45-16:45
Session 14
Hepatic Manifestations of Metabolic Syndrome: Pathophysiological and Clinical Controversies
Inflammatory manifestations in patienst with metabolic syndrome
Medical treatment of obesity in NASH with diabetes
Diabetic management of T2D and hepatic cirrhosis
Session 18
Diagnosis of T2D in Latin America
Trends and prevalance of T2D in Argentina
New diagnostic non-invasive methods in diabetes screening for Latin America (risk scores and EZScan validation in Latin America)
Session 22
Meet the Professor: Need to control Glycaemic variability
Glycaemic variability is it important?
Do we need continuous glucose monitoring
16:45-17:45
Guided Poster Tour
16:45-17:45
Clinical evidence supporting the protein diet as a tool for the medical management of excess weight: ProKal® Study results
Industrial Satellite Symposium Sponsored by Pronokal
Hall B

Sunday, March 25, 2012
Hall A
09:00-10:30
Plenary Session 23
Impact of Pregnancy Hyperglycemia on Future Cardiovascular Risk Factors
Introduction: GDM definition-implications
Obesity, hypertension and pregnancy
Pharmacological therapy in pregnancy hyperglycemia:
Oral hypoglycemic agents vs.  Insulin therapy
Maternal hyperglycemia: future impact on mothers and children
Discussion
10:30-11:00
Coffee Break
11:00-12:30
Plenary Session 24
Global Breakthroughs in the World of Diabetes

Diabetic drug interaction
GLP1, short/ long term safety
Future therapy for obesity and diabetes: Long acting GLP1/ Insulin
Stem Cell therapy: State of the art
Oral Insulin

Home    Contact Us   
 
Copyright © 2007 comtecmed.com. All rights reserved.   The website was last updated on 05/13/2012 Created by     WebStudio.co.il